What is the significance of this filing being an 'amendment' (10-K/A)?

An amendment (10-K/A) signifies that Amgen Inc. is providing updated or corrected information to its original 1997 annual report (10-K). Investors should pay close attention to the specific changes made in the amendment, as they may represent material developments or corrections to previously reported financial data or disclosures that could impact the company's reported performance or outlook.

What were Amgen's key products during the 1997 fiscal year?

While this specific filing excerpt doesn't detail the product list, Amgen's primary revenue drivers during that period were generally known to be Epogen (for anemia associated with chronic kidney disease and chemotherapy) and Neupogen (for neutropenia, a low white blood cell count).

What are the primary risks for a biotechnology company like Amgen in 1997?

Key risks for Amgen in 1997 would have included the success and market adoption of its existing products, patent expirations and challenges, regulatory hurdles for new drug approvals by the FDA, intense competition from other biotechnology and pharmaceutical companies, and the significant R&D costs associated with developing new therapies.

Where can I find the detailed financial statements and management discussion within this filing?

The provided excerpt is a directory listing of the filing's contents, not the full report. To access the detailed financial statements, Management's Discussion and Analysis of Financial Condition and Results of Operations, and other critical sections, investors would need to access the full 10-K/A filing document, typically available through the SEC's EDGAR database or Amgen's investor relations website.

AMGN 10-K FY1997 Annual Report — Revenue, Net Income, EPS

Summary

Amgen Inc.'s 1997 10-K filing, filed in May 1998, represents an amendment, indicating a potential update or correction to previously submitted information for the fiscal year ending December 30, 1997. As a leading biotechnology company, investors would be keenly interested in the company's financial health, product pipeline, regulatory approvals, and overall market position. This filing would provide insights into Amgen's revenue streams, operating expenses, profitability, and any significant developments that could impact its future performance. Key areas of focus for investors would include the commercial success of its existing products, such as Epogen and Neupogen, and any progress in the development and approval of new therapeutic agents. The competitive landscape within the biotechnology sector, potential patent expirations, and Amgen's strategic initiatives, including research and development investments and potential mergers or acquisitions, would also be critical factors influencing investor sentiment and valuation. This amended filing likely offers a more refined view of these crucial elements for the 1997 fiscal year.

Key Highlights

1Filing is an amendment to the 1997 10-K, suggesting important updates or corrections for the fiscal year ending December 30, 1997.
2Amgen Inc. operates in the biotechnology sector, a dynamic industry characterized by significant R&D investment and regulatory oversight.
3Investors would scrutinize financial performance, including revenue, expenses, and profitability, for the reporting period.
4The company's product portfolio, likely including key drugs like Epogen and Neupogen, and their market performance are critical for assessing revenue generation.
5Developments in the product pipeline, including ongoing research and clinical trials for new therapies, are crucial indicators of future growth potential.
6The filing may contain information on regulatory approvals, patent strategies, and competitive positioning within the biotechnology market.
7Any significant corporate actions, such as strategic partnerships, acquisitions, or restructuring, would be of high interest to investors.

AMGEN INC Annual Report (Amendment), Year Ended Dec 31, 1997

Summary

Key Highlights

Frequently Asked Questions